GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Stopped Study withdrawn due to lack of supply of one of the investigational agents.

Conditions

• Metastatic Melanoma
• Head and Neck Squamous Cell Carcinoma

Interventions

• DRUG: GR-MD-02
• DRUG: Placebo
• DRUG: Pembrolizumab

Sponsor

Providence Health & Services

Collaborators

• [object Object]